Gene · 990
Papers3,285
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,285
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of the expression and prognosis for RAI2: A promising biomarker in breast cancer. | Front Oncol | 2023 | 37064084 | PubTator, text mining | PubMed |
| The expanding genetic and clinical landscape associated with Meier-Gorlin syndrome. | Eur J Hum Genet | 2023 | 37059840 | PubTator, text mining | PubMed |
| CDC25A inhibition suppresses cell proliferation and induces G1/S‑phase cell cycle arrest in nasopharyngeal carcinoma. | Mol Med Rep | 2023 | 37052240 | PubTator, text mining | PubMed |
| Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma. | Int J Mol Sci | 2023 | 37047493 | PubTator, text mining | PubMed |
| Cell-Free RNA from Plasma in Patients with Neuroblastoma: Exploring the Technical and Clinical Potential. | Cancers (Basel) | 2023 | 37046768 | PubTator, text mining | PubMed |
| Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors. | Signal Transduct Target Ther | 2023 | 37041169 | PubTator, text mining | PubMed |
| Spatiotemporally resolved transcriptomics reveals the subcellular RNA kinetic landscape. | Nat Methods | 2023 | 37038000 | PubTator, text mining | PubMed |
| An in-silico approach leads to explore six genes as a molecular signatures of lung adenocarcinoma. | Am J Cancer Res | 2023 | 37034228 | PubTator, text mining | PubMed |
| Role of RUNX2 in breast cancer development and drug resistance (Review). | Oncol Lett | 2023 | 37033103 | PubTator, text mining | PubMed |
| A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. | AME Med J | 2023 | 37025121 | PubTator, text mining | PubMed |
| Mistimed origin licensing and activation stabilize common fragile sites under tight DNA-replication checkpoint activation. | Nat Struct Mol Biol | 2023 | 37024657 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| Hypoxia-mediated regulation of DDX5 through decreased chromatin accessibility and post-translational targeting restricts R-loop accumulation. | Mol Oncol | 2023 | 37013907 | PubTator, text mining | PubMed |
| A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer. | Cancer Inform | 2023 | 37008073 | PubTator, text mining | PubMed |
| Exogenous hydrogen sulfide (H2S) exerts therapeutic potential in triple-negative breast cancer by affecting cell cycle and DNA replication pathway. | Biomed Pharmacother | 2023 | 37002576 | PubTator, text mining | PubMed |
| RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. | BMC Cancer | 2023 | 36997866 | PubTator, text mining | PubMed |
Alterations in Abundance and Compartmentalization of miRNAs in Blood Plasma Extracellular Vesicles and Extracellular Condensates during HIV/SIV Infection and Its Modulation by Antiretroviral Therapy (ART) and Delta-9-Tetrahydrocannabinol (Δ9-THC). | Viruses | 2023 | 36992332 | PubTator, text mining | PubMed |
| MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. | Int J Mol Sci | 2023 | 36982482 | PubTator, text mining | PubMed |
| The BAFF-APRIL System in Cancer. | Cancers (Basel) | 2023 | 36980677 | PubTator, text mining | PubMed |
| Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies. | Cells | 2023 | 36980256 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/990/papers?page=16